Canopy Growth (CGC) Common Equity (2017 - 2026)
Canopy Growth (CGC) posted Common Equity of $508.7 million for Q1 2026, down 5.05% sequentially from $535.8 million in Q4 2025, and up 52.52% YoY from $333.5 million in Q1 2025.
Canopy Growth (CGC) Common Equity (2017 - 2026) Analysis & Trends
Canopy Growth has reported Common Equity for 10 years, with the latest figure at $508.7 million in Q1 2026.
- Quarterly Common Equity rose 52.52% year-over-year to $508.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $508.7 million (up 52.52% YoY) and the FY2026 annual result came in at $508.7 million, up 52.52% from the prior year.
- Common Equity fell to $508.7 million in Q1 2026 per CGC's latest filing, from $535.8 million in the prior quarter.
- Over five years, Common Equity peaked at $2.8 billion in Q1 2022 and troughed at $297.3 million in Q1 2024.
- A 5-year average of $709.5 million and a median of $523.7 million in 2025 frame the typical range for Common Equity.
- The sharpest annual moves came in 2023 and 2025: Common Equity sank 80.15% in 2023, then soared 53.86% in 2025.
- Over 5 years, Common Equity stood at $998.1 million in 2022, then sank by 60.63% to $393.0 million in 2023, then gained by 1.65% to $399.4 million in 2024, then jumped by 34.13% to $535.8 million in 2025, then slipped by 5.05% to $508.7 million in 2026.
- According to Business Quant data, Common Equity over the past three periods registered $508.7 million, $535.8 million, and $523.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - | 22.06 Bn |
| 2 | Teva Pharmaceutical Industries | 43.01 Bn | 39.35 Bn | 2.15 Bn | 7.76 Bn |
| 3 | Zoetis | 31.52 Bn | 29.84 Bn | 1.05 Bn | 3.15 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 47.42 Bn |
| 5 | United Therapeutics | 22.17 Bn | 19.51 Bn | 683.80 Mn | 6.40 Bn |
| 6 | Viatris | 18.73 Bn | 17.85 Bn | 1.46 Bn | 14.26 Bn |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn | 3.69 Bn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 6.59 Bn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.96 Bn | - | 4.05 Bn |
| 10 | Canopy Growth | 435.44 Mn | 188.43 Mn | 16.08 Mn | 497.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 497.83 Mn |
| Mar 31, 2026 | 508.69 Mn |
| Dec 31, 2025 | 535.76 Mn |
| Sep 30, 2025 | 523.68 Mn |
| Jun 30, 2025 | 344.25 Mn |
| Mar 31, 2025 | 333.52 Mn |
| Dec 31, 2024 | 399.44 Mn |
| Sep 30, 2024 | 340.37 Mn |
| Jun 30, 2024 | 341.53 Mn |
| Mar 31, 2024 | 297.27 Mn |
| Dec 31, 2023 | 392.98 Mn |
| Sep 30, 2023 | 543.53 Mn |
| Jun 30, 2023 | 630.93 Mn |
| Mar 31, 2023 | 562.19 Mn |
| Dec 31, 2022 | 998.12 Mn |
| Sep 30, 2022 | 1.19 Bn |
| Jun 30, 2022 | 1.29 Bn |
| Mar 31, 2022 | 2.83 Bn |
| Dec 31, 2021 | 3.29 Bn |
| Sep 30, 2021 | 3.37 Bn |